<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> (<z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> and anti-beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies, mostly IgG isotype) are strong risk factors for <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Because a paucity of information on IgA isotype exists in the literature, we retrospectively evaluated the thrombotic significance of IgA <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We included 472 patients with clinical information on thrombotic events and complete laboratory work-up for <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> syndrome </plain></SENT>
<SENT sid="3" pm="."><plain>Odds ratios (OR) of various <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> for <z:mp ids='MP_0005048'>thrombosis</z:mp> were calculated by univariate and multivariate analyses </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> alone was detected in 57 (12%) patients, ELISA-based antibodies (IgG, IgM, IgA) against <z:chebi fb="0" ids="28494">cardiolipin</z:chebi>, phosphatidylserine or beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi>-I alone were detected in 131 (28%) patients, whereas 80 (17%) patients had both </plain></SENT>
<SENT sid="5" pm="."><plain>Antibody isotype distribution was IgG 32%, IgM 60% and IgA 56% </plain></SENT>
<SENT sid="6" pm="."><plain>Univariate analysis showed a statistically significant risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> in patients with elevated titres of IgA of any ELISA-based <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (OR 1.77) </plain></SENT>
<SENT sid="7" pm="."><plain>Stepwise logistic regression (multivariate) analysis identified elevated titres of any ELISA-based IgA <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> as an independent risk factor for <z:mp ids='MP_0005048'>thrombosis</z:mp> (OR 1.6) in the entire cohort, and in the subgroup of patients without concurrent presence of <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (OR 1.8) </plain></SENT>
<SENT sid="8" pm="."><plain>IgA <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> appear to be a significant independent risk factor for <z:mp ids='MP_0005048'>thrombosis</z:mp>, thereby meriting evaluation in patients with unexpected <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
</text></document>